🔗 Share this article

The first new treatments for gonorrhoea in decades are being viewed as a "major milestone" in the effort against drug-resistant strains of the pathogen, according to scientists.

A Worldwide Challenge

The sexually transmitted infection are on the rise worldwide, with data suggesting more than 82 million infections per year. Especially elevated rates are observed in the African continent and nations within the WHO's Western Pacific region, which includes China and Mongolia to New Zealand. In England, cases have reached a all-time high, while rates across Europe in 2023 were three times higher compared to the rates from 2014.

“The authorization of novel therapies for gonorrhoea is an important and timely step in the face of increasing worldwide cases, the spread of superbugs and the extremely scarce treatment choices currently available.”

Public health authorities are deeply concerned about the increase in drug-resistant strains. The WHO has designated it as a "priority pathogen". Recent surveillance showed that the effectiveness of key first-line drugs like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

Two New Treatment Options Gain Approval

Zoliflodacin, marketed under the name Nuzolvence, was approved by the US Food and Drug Administration in December for combating gonorrhoea. This disease can lead to major issues, including the inability to conceive. Researchers believe that targeted use of this new drug will help hinder the spread of drug resistance.

Gepotidacin, created by the pharmaceutical company GSK, gained clearance in close succession. This drug, which is employed against urinary tract infections, was shown in trials to be able to combat superbug versions of the gonorrhoea bacteria.

An Innovative Development Model

Zoliflodacin emerged from a unique collaborative effort for medication research. The non-profit organisation Global Antibiotic Research & Development Partnership partnered with the drug firm Innoviva to see it through.

“This milestone marks a significant shift in the management of superbug gonorrhoea, which previously has been staying ahead of medical innovation.”

Testing Data and Global Access

As per data detailed in a major medical journal, zoliflodacin eradicated the vast majority of cases of the STI. This places it at an similar efficacy with the typical regimen, which uses two antibiotics. The study involved hundreds of participants from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its development partnership, GARDP has the authority to license and sell the drug in many low-income and middle-income countries.

Clinicians on the front lines have voiced hope. The availability of a one-pill regimen such as this is hailed as a "game-changer" for gonorrhoea control. This is viewed as vital to lessen the impact of the disease for individuals and to prevent the spread of untreatable gonorrhoea worldwide.